Guidelines for Overlap of Low‑Molecular‑Weight Heparin with Acenocoumarol

Overlap Duration and INR Targets

Initiation Timing of Acenocoumarol

Dosing of LMWH During Overlap

Renal Adjustment

Special Populations

Common Errors to Avoid

Peri‑operative Management

LMWH Overlap and Transition to Oral Anticoagulants

Overlap Duration and INR Criteria

Cancer and Other High‑Risk Populations

Direct Oral Anticoagulant (DOAC) Transition

Peri‑operative Bridging

LMWH Dosing and Monitoring

NCCN Recommendations for Enoxaparin–Warfarin Overlap in Venous Thromboembolism Management

INR Monitoring Requirements

• The National Comprehensive Cancer Network (NCCN) advises that enoxaparin should not be discontinued until two consecutive INR measurements are ≥ 2.0 (ideally 24 hours apart); a single therapeutic INR is insufficient. 7
• If the INR is still sub‑therapeutic on day 5 of overlap, enoxaparin must be continued until both consecutive INR criteria are met. 7

Enoxaparin Dosing During Overlap

• The NCCN recommends the standard therapeutic enoxaparin dose of 1 mg/kg subcutaneously every 12 hours for consistent anticoagulation. 7
• An alternative regimen of 1.5 mg/kg subcutaneously once daily may be used when appropriate. 7

Warfarin Initiation Timing

• Warfarin should be started on day 1 simultaneously with enoxaparin, using a typical initial dose of 2.5–5 mg orally daily, with subsequent adjustments based on INR results. 7

Special Populations – Cancer‑Associated VTE

• For patients with active cancer, the NCCN recommends a longer overlap of 5–7 days, maintaining enoxaparin until the INR is therapeutic on two consecutive days.
• Additionally, the NCCN strongly favors low‑molecular‑weight heparin monotherapy over warfarin for the entire treatment duration in cancer‑associated VTE. 7